Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis

References

• GoodkinDABieberBGillespieBRobinsonBMJadoulMHepatitis C infection is very rarely treated among hemodialysis patientsAm J Nephrol201338540541224192505
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the LiverEASL recommendations on treatment of hepatitis C 2016J Hepatol201766115319427667367
   PubMed Web of Science ®Google Scholar
• PockrosPJReddyKRMantryPSEfficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal diseaseGastroenterology201615071590159826976799
   PubMed Web of Science ®Google Scholar
• RothDNelsonDRBruchfeldAGrazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyLancet2015386100031537154526456905
   PubMed Web of Science ®Google Scholar
• EspinosaMMartin-MaloAAlvarez de LaraMAAljamaPRisk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patientsNephrol Dial Transplant20011681669167411477172
   PubMed Web of Science ®Google Scholar
• Kalantar-ZadehKKilpatrickRDMcAllisterCJHepatitis C virus and death risk in hemodialysis patientsJ Am Soc Nephrol20071851584159317429053
   PubMed Web of Science ®Google Scholar
• ButtAASkandersonMMcGinnisKAImpact of hepatitis C virus infection and other comorbidities on survival in patients on dialysisJ Viral Hepat2007141068869617875003
   PubMed Web of Science ®Google Scholar
• FabriziFTakkoucheBLunghiGDixitVMessaPMartinPThe impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studiesJ Viral Hepat2007141069770317875004
   PubMed Web of Science ®Google Scholar
• FabriziFDixitVBunnapradistSMartinPMeta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis populationAliment Pharmacol Ther20062381105111216611270
   PubMed Web of Science ®Google Scholar
• MathurinPMouquetCPoynardTImpact of hepatitis B and C virus on kidney transplantation outcomeHepatology19992912572639862875
   PubMed Web of Science ®Google Scholar
• MarkowitzGSChengJTColvinRBTrebbinWMD’AgatiVDHepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathyJ Am Soc Nephrol1998912224422529848778
   PubMed Web of Science ®Google Scholar
• LegendreCGarrigueVLe BihanCHarmful long-term impact of hepatitis C virus infection in kidney transplant recipientsTransplantation19986556676709521201
   PubMed Web of Science ®Google Scholar
• BruchfeldAWilczekHElinderCGHepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantationTransplantation200478574575015371680
   PubMed Web of Science ®Google Scholar
• LawitzEMangiaAWylesDSofosbuvir for previously untreated chronic hepatitis C infectionN Engl J Med2013368201878188723607594
   PubMed Web of Science ®Google Scholar
• DesnoyerAPospaiDLeMPPharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis CJ Hepatol2016651404726952005
   PubMed Web of Science ®Google Scholar
• SinghTGuirguisJAnthonySRivasJHanounehIAAlkhouriNSofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case seriesLiver Int201636680280626824848
   PubMed Web of Science ®Google Scholar
• DumortierJBaillyFPageauxGPSofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failureNephrol Dial Transplant Epub10192016
   Web of Science ®Google Scholar
• BeinhardtSAl ZoairyRFerenciPDAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation settingTranspl Int2016299999100727203857
   PubMed Web of Science ®Google Scholar
• PerumpailRBWongRJHaLDSofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysisTranspl Infect Dis201517227527825641426
   PubMed Web of Science ®Google Scholar
• SaabSMAJSNBUse of sofosbuvir-based treatment of chronic hepatitis C in liver transplant recipients on hemodialysisJ Clin Gastroenterol201751216717327548734
   PubMed Web of Science ®Google Scholar
• NazarioHENdunguMModiAASofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/minLiver Int201636679880126583882
   PubMed Web of Science ®Google Scholar
• HundemerGLSiseMEWisockyJUse of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiencyInfect Dis (Lond)2015471292492926365684
   PubMed Web of Science ®Google Scholar
• GerberLKasperDFittingDAssessment of liver fibrosis with 2-D shear wave elastography in comparison to transient elastography and acoustic radiation force impulse imaging in patients with chronic liver diseaseUltrasound Med Biol20154192350235926116161
   PubMed Web of Science ®Google Scholar
• European Medicines AgencySovaldi: Příloha I; souhrn údajů o přípravku [Sovaldi: Annex I; summary of product characteristics] Available from: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdfAccessed February 1, 2017 Czech
   Google Scholar
• European Association for the Study of the LiverEASL recommendations on treatment of hepatitis C 2015 Available from: http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/recommendations-on-treatment-of-hepatitis-c-2015Accessed February 1, 2017
   Google Scholar
• European Association for the Study of the LiverEASL recommendations on treatment of hepatitis C 2014 Available from: http://www.easl.eu/discover/news/easl-recommendations-on-treatment-of-hepatitis-c-2014Accessed February 1, 2017
   Google Scholar
• GarimellaTWangRLuoWLSingle-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairmentAntivir Ther201520553554325654812
   PubMed Web of Science ®Google Scholar
• GaneERobsonRABonacinMSafety, anti-viral-efficacy and Pharmacokinetics (PK) of Sofosbuvir (SOF) in patients with severe renal impairmentHepatology201460Suppl S1667A
   Google Scholar
• BurraPRodriguez-CastroKIMarchiniFHepatitis C virus infection in end-stage renal disease and kidney transplantationTranspl Int201427987789124853721
   PubMed Web of Science ®Google Scholar
• GeversTJBurgerDSchipper-ReintjesEKooistraMPRichterCFull-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patientsNeth J Med201674522522727323683
   PubMed Web of Science ®Google Scholar
• NelsonDRCooperJNLalezariJPAll-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyHepatology20156141127113525614962
   PubMed Web of Science ®Google Scholar
• AlonsoSRiveiro-BarcielaMFernandezIEffectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohortJ Viral Hepat201724430431127935168
   PubMed Web of Science ®Google Scholar
• WelzelTMPetersenJHerzerKDaclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohortGut201665111861187027605539
   PubMed Web of Science ®Google Scholar
• SaxenaVKoraishyFMSiseMESafety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal functionLiver Int201636680781626923436
   PubMed Web of Science ®Google Scholar
• ChlibekRSmetanaJSosovickovaRHepatitis C prevalence in the general adult population in the Czech Republic – results of a seroprevalence studyPLoS One2017124e017552528406947
   PubMed Web of Science ®Google Scholar
• SperlJFrankovaSSenkerikovaRRelevance of low viral load in haemodialysed patients with chronic hepatitis C virus infectionWorld J Gastroenterol201521185496550425987772
   PubMed Web of Science ®Google Scholar